Polaris™ Breast
Metastatic risk assessment in early, hormone receptor-positive breast cancer
RegulatoryActive
Key Facts
Indication
Metastatic risk assessment in early, hormone receptor-positive breast cancer
Phase
Regulatory
Status
Active
Company
About StratifAI
StratifAI is a Munich-based, privately-held diagnostics company developing an AI-powered biomarker discovery and validation platform for precision oncology. Founded in 2018, its flagship Polaris™ platform uses weakly supervised deep learning on multimodal data to create predictive models from routine pathology slides. The company is currently advancing its first diagnostic, Polaris™ Breast, through regulatory validation in the EU and US, backed by €14M in funding and strategic partnerships with leading oncology institutes.
View full company profile